Haematopoietic stem / progenitor cells and methods for their production
A culture system using defined growth factors and signaling agents differentiates iPSCs into CD34+ hematopoietic stem/progenitor cells with multilineage engrafting capacity, addressing the challenges of existing differentiation methods and donor-host mismatch.
Patent Information
- Application Number
- PCT/AU2025/050292
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-25
- Filing Date
- 2025-03-25
- Publication Date
- 2025-10-02
AI Technical Summary
Existing methods struggle to differentiate pluripotent stem cells into transplantable hematopoietic stem/progenitor cells with multilineage engrafting capacity, particularly due to difficulties in distinguishing between cells with and without repopulating activity, and the challenge of donor-host mismatch in allogenic transplants.
A fully defined culture system using specific growth factors and signaling agents, including WNT agonists, ACTIVIN antagonists, and retinoic acid, to guide iPSCs through a HOXA-positive differentiation pathway mimicking AGM-like hematopoiesis, resulting in CD34+ hematopoietic stem/progenitor cells capable of cryopreservation and intravenous transplantation.
The method produces hematopoietic stem/progenitor cells with multilineage engrafting capacity and repopulating activity, similar to human umbilical cord blood-derived cells, suitable for therapeutic applications.